Systems and methods for employing podocalyxin and tra human stem cell markers as prognostic markers for aggressive and metastatic cancer
OwnerWilliam Michael Schopperleinventor
Life of this patent
Estimating the term…
Abstract
The invention relates to systems and methods to detect podocalyxin-expressing and TRA-expressing cancer stem cells or cancer cells with stem cell-like properties in a tissue cell sample obtained from a localized tumor of a patient, and to determine a diagnosis or prognosis of aggressive and metastatic cancer by employing podocalyxin and TRA human stem cell markers as prognostic markers.
Claims15
A system to determine a diagnosis or prognosis of aggressive cancer cells in a patient having a localized tumor, comprising:
- a biopsy means to obtain a tissue cell sample from the localized tumor;
- a detecting means to determine the presence of podocalyxin and/or TRA expressed on cancer stem cells in the tissue cell sample;
- an indicator means to display the presence or absence of TRA-expressing cancer stem cells in the tissue cell sample;
- a medical diagnosis or prognosis of aggressive or metastatic cancer cells in the patient based on the presence of podocalyxin-expressing and/or TRA-expressing cancer stem cells in the tissue cell sample;
- and
- a medical diagnosis or prognosis of non-aggressive and localized cancer cells in the patient based on the absence of podocalyxin-expressing and/or TRA-expressing cancer stem cells in the tissue cell sample.
A method of determining a diagnosis or prognosis of aggressive cancer cells in a first patient having a localized tumor, comprising:
- obtaining a first tissue cell sample from the localized tumor;
- evaluating the first tissue cell sample for the presence of podocalyxin and/or TRA expressed on cancer stem cells;
- determining a presence or an absence of podocalyxin-expressing and/or TRA-expressing cancer stem cells in the first tissue cell sample;
- providing a positive medical diagnosis or prognosis of aggressive cancer cells for the first patient based on the presence of the podocalyxin-expressing and/or TRA-expressing cancer stem cells in the first tissue cell sample;
- and
- providing a negative medical diagnosis or prognosis of aggressive cancer cells for the first patient based on the absence of the podocalyxin-expressing and/or TRA-expressing cancer stem cells in the first tissue cell sample.
A method of selecting a medical treatment for a patient having a localized tumor, comprising:
- obtaining a tissue cell sample from the localized tumor;
- analyzing the sample for a presence of podocalyxin-expressing and/or TRA-expressing cancer stem cells selected from the group consisting of podocalyxin-specific antibodies and/or TRA-1-60, TRA-1-81 and mixtures thereof;
- determining the presence or an absence of the podocalyxin-expressing and/or TRA-expressing cancer stem cells in the sample;
- providing a positive medical diagnosis or prognosis of aggressive cancer for the patient based on the presence of the podocalyxin-expressing and/or TRA-expressing cancer stem cells in the tissue cell sample;
- and
- providing a negative medical diagnosis or prognosis of aggressive cancer for the patient based on the absence of the podocalyxin-expressing and/or TRA-expressing cancer stem cells in the tissue cell sample.
A kit for detecting and diagnosing aggressive cancer stem cells in a patient;
- the kit comprising:
- a tool for obtaining a tissue cell sample from the patient;
- an analyzing means for determining the presence or absence of podocalyxin-expressing and/or TRA-expressing cancer stem cells in the tissue cell sample;
- and
- an indicator means to display the presence or absence of the podocalyxin-expressing and/or TRA-expressing cancer stem cells in the sample.
Dependencies are inferred from the claim text.